Here, we develop and apply a semi-quantitative method for the high-confidence identification of pseudouridylated sites on mammalian mRNAs via direct long-read nanopore sequencing. A comparative analysis of a modification-free transcriptome reveals that the depth of coverage and specific k-mer sequences are critical parameters for accurate basecalling. By adjusting these parameters for high-confidence U-to-C basecalling errors, we identify many known sites of pseudouridylation and uncover previously unreported uridine-modified sites, many of which fall in k-mers that are known targets of pseudouridine synthases. Identified sites are validated using 1000-mer synthetic RNA controls bearing a single pseudouridine in the center position, demonstrating systematic under-calling using our approach. We identify mRNAs with up to 7 unique modification sites. Our workflow allows direct detection of low-, medium-, and high-occupancy pseudouridine modifications on native RNA molecules from nanopore sequencing data and multiple modifications on the same strand.

Zoledronic acid (ZOL) is a third generation bisphosphonate which can be used as a drug for the treatment of osteoporosis and metastasis. In this study, graphene oxide (GO) is conjugated with ZOL, and the nanostructured material is evaluated in terms viability, proliferation and differentiation. Furthermore, the associated morphological changes of bone marrow-derived mesenchymal stem cells (BM-MSC), and Michigan Cancer Foundation-7 (MCF-7) breast cancer cells, as well as the effect of the drugs on mineralization of BM-MSCs are investigated using a variety of characterization techniques including Fourier Transform Infrared Spectroscopy (FTIR), scanning electron microscopy (SEM) as well as alamar blue, acridine orange, and alizarin red assays. Nanostructured ZOL-GO with an optimum performance is synthesized using ZOL and GO suspensions with the concentration of 50 µM and 2.91 ng/ml, respectively. ZOL-GO nanostructures can facilitate the mineralization of BM-MSC cells, demonstrated by the formation of clusters around the cells. The results obtained confirm the performance of ZOL-GO nanostructures as promising drug complexes for the treatment of osteoporosis and metastasis.

Nanopore direct RNA sequencing (DRS) enables measurements of native RNA modifications. Modification-free transcripts are an important control for DRS. Additionally, it is advantageous to have canonical transcripts from multiple cell lines to better account for human transcriptome variation. Here we generated and analyzed Nanopore DRS datasets for five human cell lines using in vitro transcribed (IVT) RNA. We compared performance statistics amongst biological replicates. We also documented nucleotide and ionic current level variation across cell lines. These data will serve as a resource to the community for RNA modification analysis.

Enzyme-mediated chemical modifications to mRNAs have the potential to fine-tune gene expression in response to environmental stimuli. Notably, pseudouridine-modified mRNAs are more resistant to RNase-mediated degradation, more responsive to cellular stress, and have the potential to modulate immunogenicity and enhance translation in vivo. However, the precise biological functions of pseudouridine modification on mRNAs remain unclear due to the lack of sensitive and accurate tools for mapping. We developed a semi-quantitative method for mapping pseudouridylated sites with high confidence directly on mammalian mRNA transcripts via direct RNA, long-read nanopore sequencing. By analysis of a modification-free transcriptome, we demonstrate that the depth of coverage and intrinsic errors associated with specific k-mer sequences are critical parameters for accurate base-calling. We adjust these parameters for high-confidence U-to-C base-calling errors that occur at pseudouridylated sites, which are benchmarked against sites that were identified previously by biochemical methods. We also uncovered new pseudouridylated sites, many of which fall on genes that encode RNA binding proteins and on uridine-rich k-mers. Sites identified by U- to-C base calling error were verified using 1000mer synthetic RNA controls bearing a single pseudouridine in the center position, demonstrating that 1. the U-to-C base-calling error occurs at the site of pseudouridylation, and 2. the basecalling error is systematically under-calling the pseudouridylated sites. High-occupancy sites with >40% U-to-C basecalling error are classified as sites of hyper modification type I, whereas genes with more than one site of pseudouridylation are classified as having type II hyper modification which is confirmed by single-molecule analysis. We report the discovery of mRNAs with up to 7 unique sites of pseudouridine modification. Here we establish an innovative pipeline for direct identification, quantification, and detection of pseudouridine modifications and type I/II hypermodifications on native RNA molecules using long-read sequencing without resorting to RNA amplification, chemical reactions on RNA, enzyme-based replication, or DNA sequencing steps.

In this study, Zoledronic acid (ZOL), a type of nitrogen containing bisphosphonate, was loaded on graphene oxide (GO) particles to increase the particle size of the drug-nano-carrier complex which reduces drug filtration by the kidney and consequently, increases drug circulation time and its tumor uptake. The conjugation between ZOL and GO occurs via π− π stacking and hydrogen bonding interactions, and therefore, the drug may be gradually released from GO in physiological conditions which eliminates the need to apply high doses of the drug. Loading and release profile of ZOL on GO particles were investigated by using UV-Vis spectroscopy. Samples with different concentrations of 0.025-1.25 mg/ml of ZOL were loaded on 0.2 mg/ml GO. UV analysis showed that the maximum loading happens at ZOL to GO ratio of 1:0.2. This loading was obtained when 1 mg/ml of ZOL was initially loaded on 0.2 mg/ml of GO nanoparticles. The drug and drug carrier complexes were characterized by UV-vis spectroscopy.

Synthesis of RNA molecules that contain an internal site-specific modification is important for RNA research and therapeutics. While solid-state synthesis is attainable for such RNA in the range of 100 nucleotides (nts), it is currently impossible with kilobase (kb)-long RNA. Instead, long RNA with an internal modification is usually assembled in an enzymatic 3-part splint ligation to join a short RNA oligonucleotide, containing the site-specific modification, with both a left-arm and a right-arm long RNA that are synthesized by in vitro transcription. However, long RNAs have structural heterogeneity and those synthesized by in vitro transcription have 3'-end sequence heterogeneity, which together substantially reduce the yield of 3-part splint ligation. Here we describe a method of 3-part splint ligation with an enhanced efficiency utilizing a ribozyme cleavage reaction to address the 3'-end sequence heterogeneity and involving DNA disruptors proximal to the ligation sites to address the structural heterogeneity. The yields of the synthesized kb-long RNA are sufficiently high to afford purification to homogeneity for practical RNA research. We also verify the sequence accuracy at each ligation junction by nanopore sequencing.

No abstract

No abstract